Introduction and aims: Experiences of buprenorphine-naloxone (BNX) sublingual film injection are not well documented or understood. We examined how people who inject BNX film seek and share information about this practice, document the methods used to prepare BNX film for injection, and report participants' experiences of this practice. Design and Methods: Interviews were (n = 16) conducted with people who indicated that they had injected BNX film since its introduction onto the Australian market. Semistructured interviews were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the data using qualitative description methodology. Results: Participants largely reported similar BNX film preparation techniques, al...
Buprenorphine has pharmacologic advantages over methadone, especially buprenorphine's better safety ...
Background: In the last few years the number of buprenorphine users has been increasing, as well as ...
Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (O...
Introduction and Aims: Experiences of buprenorphine-naloxone (BNX) sublingual film injection are not...
Introduction and Aims Experiences of buprenorphine‐naloxone (BNX) sublingual film injection are not ...
Introduction and Aims: We report 2 years of post-marketing surveillance of the diversion and injecti...
Introduction and Aims: Buprenorphine-naloxone (BNX) film for opioid dependence treatment was introdu...
Background: Buprenorphine–naloxone sublingual film was introduced in 2011 in Australia as an alterna...
AbstractPurposeThe purpose of this study was to provide a preliminary assessment of the safety, tole...
In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone) su...
AbstractPurposeSublingual buprenorphine and combination buprenorphine/naloxone (BNX) are effective o...
Around 65% of people incarcerated in prisons in Australia, America and Europe have a history of drug...
Objectives: To examine the levels and predictors of injection of buprenorphine–naloxone (BNX) — a co...
Aims: This thesis examined non-adherence with methadone (MET), buprenorphine (BPN) and buprenorphine...
Introduction and Aims: To examine Australian opioid substitution treatment (OST) prescribers' percep...
Buprenorphine has pharmacologic advantages over methadone, especially buprenorphine's better safety ...
Background: In the last few years the number of buprenorphine users has been increasing, as well as ...
Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (O...
Introduction and Aims: Experiences of buprenorphine-naloxone (BNX) sublingual film injection are not...
Introduction and Aims Experiences of buprenorphine‐naloxone (BNX) sublingual film injection are not ...
Introduction and Aims: We report 2 years of post-marketing surveillance of the diversion and injecti...
Introduction and Aims: Buprenorphine-naloxone (BNX) film for opioid dependence treatment was introdu...
Background: Buprenorphine–naloxone sublingual film was introduced in 2011 in Australia as an alterna...
AbstractPurposeThe purpose of this study was to provide a preliminary assessment of the safety, tole...
In October 2002, the U.S. Food and Drug Administration approved buprenorphine-naloxone (Suboxone) su...
AbstractPurposeSublingual buprenorphine and combination buprenorphine/naloxone (BNX) are effective o...
Around 65% of people incarcerated in prisons in Australia, America and Europe have a history of drug...
Objectives: To examine the levels and predictors of injection of buprenorphine–naloxone (BNX) — a co...
Aims: This thesis examined non-adherence with methadone (MET), buprenorphine (BPN) and buprenorphine...
Introduction and Aims: To examine Australian opioid substitution treatment (OST) prescribers' percep...
Buprenorphine has pharmacologic advantages over methadone, especially buprenorphine's better safety ...
Background: In the last few years the number of buprenorphine users has been increasing, as well as ...
Engagement in take-home naloxone (THN) programs by people receiving opioid substitution treatment (O...